...
首页> 外文期刊>Journal of chromatography, B. Analytical technologies in the biomedical and life sciences >Application of one-step liquid chromatography-electrospray tandem MS/MS and collision-induced dissociation to quantification of ezetimibe and identification of its glucuronated metabolite in human serum: A pharmacokinetic study
【24h】

Application of one-step liquid chromatography-electrospray tandem MS/MS and collision-induced dissociation to quantification of ezetimibe and identification of its glucuronated metabolite in human serum: A pharmacokinetic study

机译:一步液相色谱-电喷雾串联MS / MS和碰撞诱导解离在依泽替米贝定量分析和人血清中葡萄糖醛酸代谢产物鉴定中的应用:药代动力学研究

获取原文
获取原文并翻译 | 示例
           

摘要

A new one-step liquid chromatography-electrospray tandem MS/MS method is described to quantify ezetimibe (EZM) a novel lipid lowering drug in human serum. Also using collision-induced dissociation (CID) of the analyte, identification and chromatographic separation of its major metabolite, ezetimibe glucuronide (EZM-G) is achieved in this study. A thawed serum aliquot of 100μL was deproteinated by addition of 500μL methanol containing omeprazole as internal standard (I.S.). Separation of the drug, its metabolite and the I.S. were achieved using acetonitrile-water (70:30, v/v) as mobile phase at flow rate of 0.5. mL/min on a MZ PerfectSil target C18 column. Multiple reaction monitoring (MRM) mode of precursor-product ion transition (408.7 → 272.0 for EZM and 345 → 194.5 for the I.S.) was applied for detection and quantification of the drug while, EZM-G was chromatographically separated and identified using CID. The analytical method was linear over the concentration range of 1-32. ng/mL of EZM in human serum with a limit of quantification of 1. ng/mL. The coefficient variation values of both inter- and intra-day analysis were less than 8% whereas the percentage error was less than 3.7. The validated method was applied in a randomized cross-over bioequivalence study of two different EZM preparations in 24 healthy volunteers.
机译:描述了一种新的一步液相色谱-电喷雾串联MS / MS方法,用于定量测定人血清中的新型降脂药物依泽替米贝(EZM)。在这项研究中,还使用了分析物的碰撞诱导解离(CID),主要代谢物ezetimibe glucuronide(EZM-G)的鉴定和色谱分离。通过加入500μL含奥美拉唑作为内标的甲醇将融化的100μL血清等分试样去蛋白(I.S.)。药物,其代谢物和I.S.的分离使用乙腈-水(70:30,v / v)作为流动相在0.5的流速下获得的目标化合物。在MZ PerfectSil目标C18柱上的mL / min。前体-产物离子转移的多反应监测(MRM)模式(EZM为408.7→272.0,IS为345→194.5)用于药物的检测和定量,而EZM-G进行了色谱分离并使用CID进行了鉴定。该分析方法在1-32的浓度范围内是线性的。 ng / mL EZM在人血清中的定量限为1. ng / mL。日间和日内分析的系数变化值均小于8%,而百分比误差小于3.7。经验证的方法应用于24名健康志愿者中两种不同EZM制剂的随机交叉生物等效性研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号